Actinium Pharmaceuticals, Inc.
www.actiniumpharma.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Actinium Pharmaceuticals shows concerning financial deterioration with cash declining from $48M to $42.1M in Q1 2026, stockholders' equity plummeting 71% from $7.8M to $2.3M, and continued zero revenue generation. Despite improved operational efficiency reducing quarterly losses from $15.9M to $5.5M, the company faces critical liquidity concerns with current burn rate.
Red Flags Detected (5)
Stockholders' equity collapsed 71% from $7.8M to $2.3M in one quarter
Cash burn of $5.9M in Q1 with zero revenue generation
Total accumulated deficit increased to $415.2M
2 more red flags detected
Key Takeaways
Company achieved 65% reduction in quarterly losses through cost management
Cash position provides limited runway at current burn rate
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.